Key Insights

Highlights

Success Rate

57% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

21.4%

3 terminated out of 14 trials

Success Rate

57.1%

-29.4% vs benchmark

Late-Stage Pipeline

14%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed with results

Key Signals

57% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (4)
P 1 (1)
P 2 (3)
P 4 (2)

Trial Status

Completed4
Terminated3
Unknown3
Withdrawn2
Recruiting1
Not Yet Recruiting1

Trial Success Rate

57.1%

Benchmark: 86.5%

Based on 4 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04648267Not ApplicableCompletedPrimary

Factors Affecting Split Thickness Skin Graft Success Rates in Patients Who Underwent a Radial Forearm or Fibula Free Flap

NCT06379724Phase 4Recruiting

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

NCT06766474Phase 2CompletedPrimary

The Rule of Bupivacaine Hydrochloride in Skin Graft Donor Site

NCT06134843Phase 1Not Yet RecruitingPrimary

Study to Assess the Safety and Efficacy of DERMASEAL for the Treatment of Split-Thickness Skin Graft Donor Site Wounds

NCT03937765Not ApplicableTerminated

The Effect of Platelet Rich Plasma on Pain at Skin Graft Donor Sites

NCT06170424Completed

Retrospective Analysis of Spray Skin Treats for Severe Burns

NCT05447793Unknown

Effectiveness and Tolerability of Fitostimoline Plus vs Connettivina Bio Plus in Skin Graft

NCT05367726Unknown

The Contributions of the Multidisciplinary Management of Prosthesis Knee Infections in a Reference Center: A Retrospective Study About 52 Cases.Skin Coverage in a Reference Center: A Retrospective Study About 52 Cases

NCT01983085Phase 2Terminated

Nitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds

NCT04014400Not ApplicableTerminated

Suprathel Versus Xeroform for the Management of Skin Graft Donor Sites

NCT03548610Not ApplicableWithdrawn

Efficacy and Safety of a Nanofat-seeded Biological Scaffold in Healing Lower Limb Surgical Defects

NCT04231305CompletedPrimary

Antithrombotics and Complications in Skin Grafts

NCT04186273Phase 2Unknown

Clinical Safety and Scar Prevention Study of a Topical Antifibrotic Compound FS2.

NCT02994589Phase 4WithdrawnPrimary

A Comparison of OASIS Wound Matrix With Approved Dressings for Skin Graft Donor Sites

Showing all 14 trials

Research Network

Activity Timeline